Low-cost drug management policy introduced

Some people have described that the New Drug Reform Policy introduced by the Development and Reform Commission will give these "lifesaving pills" to these lifesaving medicines and low-cost medicines. Pharmaceutical companies and medical institutions how to see? Can this new policy really work out the effectiveness of the quick-effective Jiuxin pill?

Many pharmaceutical companies in Henan have products in the list

Henan is a recognized province of medicine. Data published on the official website of Henan Food and Drug Administration shows that there are more than 300 pharmaceutical production enterprises in our province, and there are more than 300 pharmaceutical wholesale companies, and Henan Province Many of these more than 300 drug manufacturers have produced low-priced drugs.

A person in charge of Furen Pharmaceutical Group Co., Ltd. said that after the National Development and Reform Commission issued the "Notice on improving the management of low-priced drug prices," they will first produce drugs and within the pricing range of the National Development and Reform Commission. The list of low-priced medicines was compared. It was finally determined that the company had 102 varieties of medicines among the list of 533 low-priced medicines announced by the National Development and Reform Commission, including 90 medicines for western medicine and 12 medicines for proprietary Chinese medicines.

According to the person in charge, Furen Pharmaceutical is one of the pharmaceutical companies in China that produce more low-cost drugs. However, the person in charge also said that some of the low-priced drugs had previously been discontinued.

From Henan Province Wanxi Pharmaceutical Co., Ltd. learned that the company also has nearly 30 kinds of drugs in the list of low-priced drugs issued by the National Development and Reform Commission. A person in charge of the company admitted frankly that treatment such as Danshen Pills (pieces) and Naoxuekang Some of the low-cost medicines for cardiovascular and cerebrovascular diseases are currently in a state of non-production.

[Pharmaceuticals]

The return of low-cost drugs also has to protect the hospital

The frequent use of low-cost, commonly used drugs is a common practice in the industry.

When a drug company from a province in the province that had produced him was asked about the reasons for the discontinuation of him, the other party simply said “I don’t make money from this drug” and he hung up.

The relevant person in charge of Fu Jen Pharmaceutical also stated that the price of low-priced drugs is too low, and the cost of producing low-priced drugs for companies is close to the retail price and sometimes even higher than the retail price, so that the low-priced drugs produced If you do not make money or even lose money, many pharmaceutical companies will gradually give up the production of cheap drugs.

“The production of the same low-priced drugs, some large pharmaceutical companies such as Fu Jen compared with those of smaller pharmaceutical companies, the requirements on the production process and quality standards must be more stringent, and the corresponding input costs should be greater. The profits of the enterprises will be relatively low, and the enthusiasm for producing low-priced drugs over time will be low."

"This time our company has so many products in the list of low-priced drugs. It is good news for us. The relevant drugs will be used more widely and will have a positive impact on the market expansion of the company's products." However, The person in charge of Fu Jen Pharmaceutical also said that low-priced drugs can not return to the market, but also have to look at how to proceed with the tender, and how to protect the hospital.

【hospital】

To take care of medicine hospitals are more willing to choose expensive drugs

In the same way, because of the low profits, there are also many cases in hospitals that are reluctant to use low-priced drugs.

A hospital doctor in Zhengzhou, who did not wish to be named, also said that many hospitals are still in the status of “taking drugs to support medicine”. These cheap drugs are in hospitals and can only be sold at a fair price. "Without profits, the hospital would not be willing to use them, instead choosing more expensive alternative drugs and imported drugs."

According to reports, in addition to the elimination of 15% of drug additions in all 52 general hospitals in 40 pilot counties (cities) in China, many hospitals still implement drug addition policies. Drugs from suppliers to patients have 15% bonus. This means that the higher the price of medicines, the higher the hospital's income.

For example, if you add 15% of the drug for a bottle of 100 yuan, the hospital can earn 15 yuan, and even if you add 100 yuan per bottle, you can only earn 1 yuan. "Generally, drugs with a price of less than 500 yuan will increase 15%, drugs with a price of 500 yuan or more will add 75 yuan," the doctor said.

The responsible person of the National Development and Reform Commission stated that relevant departments will further improve the bidding procurement policy for low-priced drugs to ensure that reasonable prices are formed through competition. At the same time, he also pointed out that there is a certain substitute relationship between low-priced drugs and high-priced drugs, and a reasonable adjustment of the prices of low-priced drugs is conducive to mobilizing the enthusiasm of enterprises to produce and supply low-priced drugs. It is also beneficial to medical institutions to optimize the use of drugs.

sound

The New Deal is not "Quick Effect Pills"

“The government's decision to liberalize low drug prices can change the current situation in which hospitals are reluctant to use drugs and pharmaceutical companies are reluctant to produce low-priced drugs. The key lies in whether the benefits of hospitals and drug companies can be guaranteed.” Central China Institute of Technology Professor Wang Zhimin believes that the NDRC’s new policy enthusiasm is there, but it is not a “quick-effect rescue pill” for saving low-priced drugs.

Wang Zhimin stated that for pharmaceutical companies, if they cannot reserve a reasonable profit margin for them, it will be difficult to really mobilize their production enthusiasm. For hospitals, hospitals and doctors are subjectively reluctant to use many low-priced classic drugs without a certain amount of benefit compensation before the “medicine-for-medicine” mechanism has been completely changed.

Suggest

Speed ​​up medical reform

Take a "differentiated" policy

"To change the issue of low-cost medicines, if they are not good or bad, on the one hand, it is necessary to speed up the medical reform, so that the hospital is willing to purchase, doctors are willing to prescribe." Wang Zhimin said that at present, we should try to mobilize the medical institutions to give priority to the use of cheap drugs. Drug purchases should also increase the participation of medical institutions, encourage hospitals to purchase low-cost medicines at preferential prices, and ensure high-quality services to ensure timely delivery of low-cost drugs. At the same time, it is necessary to establish a scientific public hospital salary system to avoid directly linking the income of medical personnel with the incomes of prescribing medicines, inspections and treatments, and guide medical personnel to use inexpensive and high-quality drugs through reasonable performance assessment.

On the other hand, in order to ensure adequate supply of low-cost drugs, a “differential treatment” policy can be adopted.

Wang Zhimin stated that for some low-price drugs with sufficient competition, pharmaceutical companies should be allowed to set prices independently in accordance with relevant conditions, so as to mobilize their production enthusiasm. For those low-priced drugs that use less, the government should give companies that produce these low-priced drugs a reasonable "compensation for benefits," and use "interest-recovery mechanisms" to ensure that companies can provide sufficient supplies. For those low-priced drugs that only a few pharmaceutical companies can supply and have insufficient competition, in order to avoid the phenomenon of high drug prices, the price of "production cost plus" can be adopted. The government organizes professionals to account for the true cost of drugs, minimize circulation, and monitor the spread of each link of the drug.